GlassScriptPhysician profile
Darshil J Shah
NPI 1710192489
$61,938.91
in general payments reported to CMS, 2019-2025
77 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,026 · 2020: $1,164 · 2021: $4,048 · 2022: $4,670 · 2023: $5,140 · 2024: $14K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $14K · Food and Beverage: $9,767 · Travel and Lodging: $1,825 · Long Term Medical Supply Or Device Loan: $167 · Education: $95.00 · Gift: $20.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,049.00 |
| Consulting Fee | $14,108.00 |
| Food and Beverage | $9,767.14 |
| Travel and Lodging | $1,824.84 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $95.00 |
| Gift | $20.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20,319.18 | 2020-2025 | |
| Ipsen Biopharmaceuticals, INC | $7,524.23 | 2019-2025 | Onivyde, Somatuline Depot |
| Amgen INC. | $5,051.96 | 2019-2025 | Vectibix, Vectibix, Xgeva |
| Gilead Sciences, INC. | $2,612.67 | 2019-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $2,115.19 | 2019-2025 | |
| Beone Medicines USA, INC. | $1,985.92 | 2025 | Tevimbra, Brukinsa |
| US Oncology Corporate, INC. | $1,727.30 | 2023 | |
| Rigel Pharmaceuticals, INC. | $1,706.05 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Tempus Ai, INC | $1,702.16 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $1,325.57 | 2019-2025 | Polivy, Alecensa, Columvi |
| Incyte Corporation | $1,277.87 | 2019-2025 | Zynyz, Jakafi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $1,219.65 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $1,182.34 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $1,085.97 | 2019-2025 | |
| Celgene Corporation | $1,041.70 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.10 | 2019-2025 | Venclexta |
| Astellas Pharma US INC | $638.10 | 2019-2025 | Padcev, Xospata, Vyloy |
| Genzyme Corporation | $594.69 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $576.90 | 2019-2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $547.52 | 2019-2023 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $536.03 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $378.05 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $352.82 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $350.06 | 2019-2024 | Ninlaro, Fruzaqla, Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $337.77 | 2019-2025 | |
| Exelixis INC. | $325.70 | 2019-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $285.48 | 2019-2025 | Ultomiris |
| Blueprint Medicines Corporation | $271.98 | 2020-2025 | Ayvakit |
| Seagen INC. | $269.48 | 2019-2023 | Tukysa, Padcev |
| Array Biopharma INC | $245.36 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Genmab U.S., INC. | $217.97 | 2024-2025 | Tivdak, Epkinly |
| Regeneron Healthcare Solutions, INC. | $211.18 | 2021-2023 | Libtayo |
| Taiho Oncology, INC. | $200.91 | 2021-2025 | |
| Glaxosmithkline, LLC. | $185.14 | 2021-2025 | Shingrix, Zejula, Jemperli |
| Tersera Therapeutics LLC | $184.79 | 2021-2025 | Zoladex |
| Eisai INC. | $183.11 | 2019-2024 | |
| Sirtex Medical INC | $179.79 | 2023 | Sir-Spheres Microspheres |
| Novocure INC. | $168.71 | 2024 | Optune Lua (Novottf-200t) |
| Puma Biotechnology, INC. | $161.00 | 2019-2023 | |
| Emd Serono, INC. | $148.74 | 2020-2025 | Bavencio, Tepmetko |
| Phathom Pharmaceuticals, INC. | $132.80 | 2024 | Voquezna |
| Mirati Therapeutics, INC. | $120.14 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.00 | 2019-2023 | Gilotrif |
| Clovis Oncology, INC. | $109.92 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $109.81 | 2021-2023 | |
| Sobi, INC | $100.12 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $94.02 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $85.31 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $79.64 | 2022-2024 | Fotivda |
| Springworks Therapeutics, INC. | $73.44 | 2024 | Ogsiveo |
| Kyowa Kirin, INC. | $63.13 | 2020-2022 | |
| Myovant Sciences INC. | $60.14 | 2021 | |
| Foundation Medicine, INC. | $57.43 | 2019-2021 | |
| Kite Pharma, INC. | $57.08 | 2025 | Yescarta |
| Pharmaessentia USA Corporation | $54.86 | 2025 | Besremi |
| G1 Therapeutics, INC. | $52.73 | 2022 | |
| Adaptive Biotechnologies Corporation | $51.19 | 2023-2024 | Clonoseq |
| Karyopharm Therapeutics INC. | $46.95 | 2020-2024 | Xpovio |
| Beigene USA, INC. | $44.24 | 2023-2025 | Brukinsa, Tevimbra |
| Acrotech Biopharma INC. | $30.87 | 2021 | |
| Geron Corporation | $27.65 | 2024 | Rytelo |
| Progenics Pharmaceuticals, INC. | $25.28 | 2024 | |
| Stemline Therapeutics INC. | $23.59 | 2024 | Orserdu |
| Morphosys, US INC. | $23.10 | 2021 | |
| Coherus Oncology, INC. | $22.90 | 2022 | |
| Servier Pharmaceuticals LLC | $22.89 | 2025 | |
| Deciphera Pharmaceuticals INC. | $21.98 | 2024 | Qinlock |
| Adc Therapeutics America, INC. | $21.95 | 2024 | |
| Shire North American Group INC | $21.31 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.18 | 2022 | |
| Verastem, INC. | $16.86 | 2020 | |
| Immunocore Limited | $16.06 | 2025 | Kimmtrak |
| Tolmar Pharmaceuticals, INC. | $15.41 | 2022 | |
| Mayne Pharma Commercial LLC | $14.60 | 2021 | |
| Advanced Accelerator Applications | $12.22 | 2019 | |
| Iovance Biotherapeutics, INC. | $12.11 | 2025 | Amtagvi |
| Teva Pharmaceuticals USA, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshil Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.